HOME >> BIOLOGY >> NEWS
JCI Table of Contents, March 14, 2003

cell markers in the peripheral blood, Catherine Verfaillie and colleagues tested peripheral blood from patients during acute crisis and chronic stages of disease for the presence of primitive hematopoietic progenitors (pages 811819). They found that during acute crisis, patients spontaneously mobilize significant numbers of progenitors with multiple-lineage and repopulation potential into the peripheral blood, suggesting that collection of these progenitors could yield a source of autologous cells suitable for genetic manipulation and subsequent transplantation.

CONTACT:
Catherine M. Verfaillie
University of Minnesota
MMC 716
420 Delaware Street SE
Minneapolis, MN 55455
USA
Phone 1-612-624-3921
Fax 1: 612-624-2436
E-mail: verfa001@tc.umn.edu

View the PDF of this article at: https://www.the-jci.org/press/15956.pdf

Mismatch repair awry in lung cancer

Mutations in DNA mismatch repair genes cause inherited colon cancer syndromes, and somatic mutations and promoter methylation of these genes have been found in a variety of human cancers characterized by microsatellite instability (MSI). Having previously shown that MSI and loss of hMLH1 protein expression is common in lung cancer patients from Taiwan, Yi-Ching Wang and colleagues now report (pages 887895) results from a comprehensive genetic and epigenetic analysis of 77 resected primary non-small cell lung tumors. Of these tumors, 70% had lost expression of either hMLH1 or hMSH2, and promoter methylation seemed to be the predominant cause. Moreover, promoter methylation of hMLH1 (whose expression is lost in over 50% of the samples) appears to be an early event in tumorigenesis and can be detected in sputum samples. Thus it might serve as a potential diagnostic marker.

<
'"/>

Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
14-Mar-2003


Page: 1 2 3 4 5 6 7

Related biology news :

1. JCI Table of Contents, 15 July 2004
2. JCI Table of Contents, January 15 2004
3. JCI Table of Contents, November 3, 2003
4. JCI Table of Contents, 1 October, 2003
5. JCI Table of Contents, September 15, 2003
6. JCI Table of Contents
7. JCI Table of Contents, 15 August 2003
8. JCI Table of Contents, May 1, 2003
9. JCI Table of Contents, April 1, 2003
10. JCI Table of Contents, January 2, 2003
11. JCI Table of Contents, December 2, 2002

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: JCI Table Contents March

(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
(Date:11/18/2014)... YORK , Nov. 18, 2014   ... identity authentication solutions, and MorphoTrust USA ... and services, today announced a strategic partnership to ... enterprise, motor vehicle administration (MVA), airport screening and ... in identity-related solutions, MorphoTrust serves consumers through a ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
(Date:12/17/2014)... Ipsen Biopharmaceuticals, Inc., an affiliate ... IPSEY), today announced that Somatuline® Depot® (lanreotide) ... approved by the U.S. Food and Drug Administration ... (GEP-NETs) in adult patients with unresectable, well or ... improve progression-free survival (PFS). , “The approval of ...
(Date:12/17/2014)... IN (PRWEB) December 17, 2014 ... Laboratory Excellence following its most recent COLA inspection. ... by COLA, a national healthcare accreditation organization. Accreditation ... standards of quality in day-to-day operations, demonstrate continued ... pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... 2014  Vermillion, Inc. (NASDAQ: VRML ), ... announced the next step in its expanded strategy to ... with the naming of current Chief Operating Officer, ... while current Chairman of the Board and CEO ... These changes are effective January 1, 2015. ...
(Date:12/17/2014)... 17, 2014 Tigercat Pharma, Inc. today ... evaluating the investigational oral NK-1 receptor antagonist VPD-737 ... chronic itch who are unresponsive or inadequately responsive ... steroids and antihistamines. The primary ... Scale (VAS) itch score from baseline, comparing drug ...
Breaking Biology Technology:Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
Cached News: